|
KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - NantWorks |
|
|
|
Stock and Other Ownership Interests - NantWorks |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - NantWorks |
Patents, Royalties, Other Intellectual Property - NantWorks |
|
|
Honoraria - Amgen; Foundation Medicine; Genentech/Roche; Genmab; Lilly; OncoPlex Diagnostics; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics |
Speakers' Bureau - Foundation Medicine; Lilly; OncoPlex Diagnostics |
Research Funding - Amgen; Genentech; OncoPlex Diagnostics |